GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE -/- mice

Endocrinology

Volumn 154, Issue 1, 2013, Pages 127-139

  Panjwani, Naim ^a   Mulvihill, Erin E ^a   Longuet, Christine ^a   Yusta, Bernardo ^a   Campbell, Jonathan E ^a   Brown, Theodore J ^a   Streutker, Catherine ^b   Holland, Dianne ^a   Cao, Xiemin ^a   Baggio, Laurie L ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; COMPLEMENTARY DNA; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MESSENGER RNA; METFORMIN; STREPTOZOCIN; TASPOGLUTIDE; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE EXPRESSION; LIPID STORAGE; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; BODY COMPOSITION; GLUCOSE TOLERANCE TEST; HEPATOCYTES; INTERLEUKIN-10; LIVER; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; PEPTIDES; RECEPTORS, GLUCAGON;

EID: 84871686739     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1937     Document Type: Article

References (49)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR 2012 Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379
2. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
3. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ 2009 GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983
4. Ussher JR, Drucker DJ 2012 Cardiovascular biology of the incretin system. Endocr Rev 33:187-215
5. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T 2012 The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 9:209-222
6. Drucker DJ, Goldfine AB 2011 Cardiovascular safety and diabetes drug development. Lancet 11:977-979
7. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H 2010 Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1037
8. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H 2012 A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59:265-276
9. -/- mice. Diabetologia 55:2267-2275
10. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T 2011 Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54:2649-2659
11. Bornfeldt KE, Tabas I 2011 Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14:575-585
12. Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ 2009 Differential importance of GIP versus GLP-1 receptor signaling for β-cell survival in mice. Gastroenterology 137:2146-2157
13. Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ 2010 Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes 59:1063-1073
14. Maida A, Lamont BJ, Cao X, Drucker DJ 2011 Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54:339-349
15. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nature Med 2:1254-1258
16. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ 2004 Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335 (Pubitemid 38569020)
17. Flock G, Baggio LL, Longuet C, Drucker DJ 2007 Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56:3006-3013 (Pubitemid 350223636)
18. Rodbell M 1964 Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375-380
19. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338-1349 (Pubitemid 351397945)
20. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ 2006 GLP-1 receptor activation improves β-cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391-406 (Pubitemid 44752565)
21. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500 (Pubitemid 39145610)
22. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ 2012 Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 122:388-402
23. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K 2010 The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion. Diabetologia 53:552-561
24. Daugherty A, Whitman SC 2003 Quantification of atherosclerosis in mice. Methods Mol Biol 209:293-309
25. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321 (Pubitemid 40770284)
26. Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, Cawthorne MA, Culler MD 2010 Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 151:2474-2482
27. Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA 2012 GLP-1 analogue, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet. Am J Physiol Gastrointest Liver Physiol 302:G225-G335
28. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M 2011 Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 54:3093-3100
29. Baggio LL, Huang Q, Cao X, Drucker DJ 2008 The long-acting albumin-exendin-4 GLP-1R agonist CJC-1134 engages central and peripheral mechanisms regulating glucose homeostasis. Gastroenterology 134:1137-1147 (Pubitemid 351451971)
30. Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE 2012 Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab 302:E334-E343
31. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA 2010 Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584-1592
32. Flamez D, Van Breusegem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ, Schuit F 1998 Mouse pancreatic β-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide 1 receptor gene. Diabetes 47:646-652 (Pubitemid 28160457)
33. Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyazaki A, Hirano T 2012 Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 61:974-977
34. Liang CP, Han S, Li G, Tabas I, Tall AR 2012 Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment. Diabetes 61:2609-2620
35. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, Ha SY, Kang Y, Kim Y, Jun HS 2012 Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55:2456-2468
36. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H 2011 Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965-978
37. Bullock BP, Heller RS, Habener JF 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137:2968-2978 (Pubitemid 26192194)
38. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A 2011 Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31:1285-1297
39. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA 2011 GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6:e25269
40. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S 2011 Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54:1214-1223
41. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY 2012 Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 7:e31394
42. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD 2012 Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302:G762-G772
43. Parlevliet ET, Schröder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H 2009 CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 328:240-248
44. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H 2010 GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 299:E318-E324
45. Ding X, Saxena NK, Lin S, Gupta NA, Gupta N, Anania FA 2006 Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43:173-181 (Pubitemid 43733604)
46. Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ 2005 LXRs regulate the balance between fat storage and oxidation. Cell Metab 1:231-244 (Pubitemid 43960607)
47. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S 2009 Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 284:33509-33520
48. Dunphy JL, Taylor RG, Fuller PJ 1998 Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141:179-186 (Pubitemid 28393391)
49. Tomas E, Stanojevic V, Habener JF 2010 GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42:657-662